PL2199390T3 - Anti-epha2 antibody - Google Patents

Anti-epha2 antibody

Info

Publication number: PL2199390T3
Authority: PL; Poland
Prior art keywords: epha2 antibody; epha2; antibody
Prior art date: 2007-08-30

Application number

PL08828482T

Other languages

Polish (pl)

Original Assignee

Daiichi Sankyo Company, Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-30

Filing date

2008-08-29

Publication date

2017-06-30

2008-08-29 Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited

2017-06-30 Publication of PL2199390T3 publication Critical patent/PL2199390T3/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

PL08828482T 2007-08-30 2008-08-29 Anti-epha2 antibody PL2199390T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2007224007		2007-08-30
EP08828482.3A EP2199390B1 (en)	2007-08-30	2008-08-29	Anti-epha2 antibody

Publications (1)

Publication Number	Publication Date
PL2199390T3 true PL2199390T3 (en)	2017-06-30

Family

ID=40387351

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL08828482T PL2199390T3 (en)	2007-08-30	2008-08-29	Anti-epha2 antibody

Country Status (26)

Country	Link
US (3)	US8449882B2 (en)
EP (1)	EP2199390B1 (en)
JP (2)	JP5312333B2 (en)
KR (4)	KR101561403B1 (en)
CN (1)	CN101848998B (en)
AU (1)	AU2008292352B2 (en)
BR (1)	BRPI0816094A2 (en)
CA (1)	CA2698146C (en)
CO (1)	CO6180469A2 (en)
CY (1)	CY1118763T1 (en)
DK (1)	DK2199390T3 (en)
ES (1)	ES2618316T3 (en)
HR (1)	HRP20170407T1 (en)
HU (1)	HUE032301T2 (en)
IL (1)	IL204211A (en)
LT (1)	LT2199390T (en)
MX (1)	MX2010002248A (en)
MY (1)	MY150621A (en)
NZ (1)	NZ583966A (en)
PL (1)	PL2199390T3 (en)
PT (1)	PT2199390T (en)
RU (1)	RU2525133C2 (en)
SI (1)	SI2199390T1 (en)
TW (1)	TWI443109B (en)
WO (1)	WO2009028639A1 (en)
ZA (1)	ZA201001340B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8518405B2 (en)	2009-10-08	2013-08-27	The University Of North Carolina At Charlotte	Tumor specific antibodies and uses therefor
WO2012008397A1 (en) *	2010-07-12	2012-01-19	第一三共株式会社	Anti-epha2 antibody and use thereof
US9220772B2 (en)	2010-07-22	2015-12-29	The Regents Of The University Of California	Anti-tumor antigen antibodies and methods of use
EP2446895A1 (en) *	2010-10-01	2012-05-02	Stemgen S.P.A.	EPH receptor expression in tumor stem cells
US9845362B2 (en)	2010-10-08	2017-12-19	The University Of North Carolina At Charlotte	Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
DK2686020T3 (en)	2011-03-17	2017-05-01	Univ Birmingham	REDIRECTED IMMUNTERY
JP5875054B2 (en)	2013-02-13	2016-03-02	国立大学法人東京大学	Cancer testing method and testing kit
US11554181B2 (en)	2014-09-05	2023-01-17	The University Of North Carolina At Charlotte	Tumor specific antibody conjugates and uses therefor
EP3442566A4 (en) *	2016-04-14	2019-11-20	Academia Sinica	INHIBITION OF SCUBE2, A NEW CO-RECEPTOR OF VEGFR2, REMOVING TUMOR ANGIOGENESIS
EP3468587A4 (en) *	2016-06-09	2020-02-19	University of Leicester	MONOCLONAL ANTIBODIES, COMPOSITIONS AND METHODS FOR DETECTION OF MUCIN-LIKE PROTEIN (MLP) AS A BIOMARKER FOR OVARIAN CANCER AND PANCREAS
CN110198956A (en) *	2017-01-23	2019-09-03	学校法人东洋大学	Anti-EPHA 2 antibody and the EPHA2 immune detection for using the anti-EPHA 2 antibody
EP3661552A4 (en) *	2017-05-22	2021-08-25	Dana-Farber Cancer Institute, Inc.	COMPOSITIONS AND METHODS FOR INHIBITING MICA / B REJECTION
CN109879965B (en) *	2017-12-06	2022-11-11	北京科立思维生物科技有限公司	anti-EPHA 2 single-chain antibody, anti-CD 3E single-chain antibody, fusion protein and application thereof
US12448426B2 (en)	2018-05-17	2025-10-21	St. Jude Children's Research Hospital, Inc.	Chimeric antigen receptors with MYD88 and CD40 costimulatory domains
SMT202500141T1 (en)	2018-09-06	2025-05-12	Daiichi Sankyo Co Ltd	Antibody-drug conjugates of cyclic dinucleotide derivatives
US11702482B2 (en)	2018-12-17	2023-07-18	Revitope Limited	Twin immune cell engager
TW202241454A (en)	2021-02-01	2022-11-01	日商第一三共股份有限公司	Novel method for producing antibody-immunostimulator conjugate
EP4301785A4 (en) *	2021-03-05	2025-04-23	Atreca, Inc.	Epha2 antibodies
BR112023017365A2 (en)	2021-03-12	2023-10-03	Daiichi Sankyo Co Ltd	GLYCAN AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN
WO2022250431A1 (en)	2021-05-25	2022-12-01	주식회사 박셀바이오	Monobody-based chimeric antigen receptor and immune cell including same
CN115505041A (en) *	2021-06-22	2022-12-23	北京免疫方舟医药科技有限公司	anti-EphA 2 antibodies and uses thereof
AU2023229142A1 (en)	2022-03-02	2024-10-03	Daiichi Sankyo Company, Limited	METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
WO2024053574A1 (en)	2022-09-09	2024-03-14	第一三共株式会社	Novel oligosaccharide, production intermediate for novel oligosaccharide, production method for novel oligosaccharide, and production method for production intermediate for novel oligosaccharide

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
DK0585287T3 (en)	1990-07-10	2000-04-17	Cambridge Antibody Tech	Process for producing specific binding pair elements
DE69229477T2 (en)	1991-09-23	1999-12-09	Cambridge Antibody Technology Ltd., Melbourn	Methods for the production of humanized antibodies
ATE463573T1 (en)	1991-12-02	2010-04-15	Medimmune Ltd	PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
CA2131151A1 (en)	1992-03-24	1994-09-30	Kevin S. Johnson	Methods for producing members of specific binding pairs
GB9313509D0 (en)	1993-06-30	1993-08-11	Medical Res Council	Chemisynthetic libraries
AU690171B2 (en)	1993-12-03	1998-04-23	Medical Research Council	Recombinant binding proteins and peptides
US6214388B1 (en)	1994-11-09	2001-04-10	The Regents Of The University Of California	Immunoliposomes that optimize internalization into target cells
JP4436457B2 (en)	1995-08-18	2010-03-24	モルフォシスアイピーゲーエムベーハー	Protein / (poly) peptide library
US6972323B1 (en)	1997-04-01	2005-12-06	Sankyo Company, Limited	Anti-Fas antibodies
PT1144607E (en)	1999-07-20	2009-04-22	Morphosys Ag	Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
EP2312316A1 (en)	1999-08-17	2011-04-20	Purdue Research Foundation	Anti-EPHA2 antibodies as a cancer diagnostic
ATE324877T1 (en) *	1999-08-17	2006-06-15	Purdue Research Foundation	TREATMENT OF METASTATIC DISEASE
AU2001256970C1 (en)	2000-03-31	2008-07-03	Purdue Research Foundation	Method of treatment using ligand-immunogen conjugates
US20020025536A1 (en)	2000-06-26	2002-02-28	Jeno Gyuris	Methods and reagents for isolating biologically active antibodies
US7101976B1 (en) *	2000-09-12	2006-09-05	Purdue Research Foundation	EphA2 monoclonal antibodies and methods of making and using same
ES2620359T3 (en)	2000-10-06	2017-06-28	Kyowa Hakko Kirin Co., Ltd.	Cells that produce antibody compositions
JP4799816B2 (en) *	2001-06-05	2011-10-26	ヴァレオ	Locking device with transmission gear
JP2005500034A (en)	2001-06-20	2005-01-06	プロションバイオテクリミテッド	Antibody that blocks activation of receptor protein tyrosine kinase, screening method thereof, and use thereof
US20040247592A1 (en)	2001-07-03	2004-12-09	Roifman Chaim M.	Ephrin and eph receptor mediated immune modulation
FR2838742B1 (en) *	2002-04-23	2004-07-09	Inst Nat Sante Rech Med	EPITOPES T OF THE EPHA2 ANTIGEN
US20050152899A1 (en) *	2002-05-10	2005-07-14	Kinch Michael S.	EphA2 agonistic monoclonal antibodies and methods of use thereof
EP1575509B1 (en)	2002-05-10	2011-10-26	Purdue Research Foundation	Epha2 agonistic monoclonal antibodies and methods of use thereof
AU2003243228B2 (en) *	2002-05-10	2009-03-26	Medimmune, Llc	EphA2 monoclonal antibodies and methods of use thereof
JP2006501153A (en)	2002-05-23	2006-01-12	パーデュー・リサーチ・ファウンデーション	Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target
US7326552B1 (en) *	2002-06-21	2008-02-05	Takeda San Diego, Inc.	Wild-type kinase domain of human Ephrin receptor A2 (EPHA2) and crystallization thereof
EP1852441B1 (en)	2002-09-24	2012-03-28	The Burnham Institute	Agents that modulate EPH receptor activity
CA2499580A1 (en)	2002-09-24	2004-04-08	The Burnham Institute	Novel agents that modulate eph receptor activity
JP4589914B2 (en)	2003-01-07	2010-12-01	シムフォゲン・アクティーゼルスカブ	Method for producing recombinant polyclonal protein
AU2003900541A0 (en)	2003-02-07	2003-02-20	Ludwig Institute For Cancer Research	Modulation of cell adhesion and tumour cell metastasis
KR20110094361A (en)	2003-04-11	2011-08-23	메디뮨 엘엘씨	Recombinant IL-1 antibodies and uses thereof
EP1618184A4 (en)	2003-04-11	2006-06-21	Medimmune Inc	Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
US20050059592A1 (en)	2003-04-11	2005-03-17	Kiener Peter A.	EphA2 and hyperproliferative cell disorders
US8012681B2 (en)	2003-05-13	2011-09-06	Novartis Vaccines And Diagnostics, Inc.	Methods of modulating metastasis and skeletal related events resulting from metastases
US20050147593A1 (en)	2003-05-22	2005-07-07	Medimmune, Inc.	EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
CA2523716C (en)	2003-05-31	2014-11-25	Micromet Ag	Human anti-human cd3 binding molecules
US20050009033A1 (en)	2003-07-08	2005-01-13	The Regents Of The University Of California	Breast cancer genes
WO2005016381A2 (en)	2003-07-21	2005-02-24	Medimmune, Inc.	Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
EP1651671A2 (en)	2003-07-30	2006-05-03	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Epha2 t-cell epitope agonists and uses therefor
JP4934426B2 (en) *	2003-08-18	2012-05-16	メディミューン，エルエルシー	Antibody humanization
JP2007528723A (en)	2003-08-22	2007-10-18	メディミューン，インコーポレーテッド	Antibody humanization
AU2004281834A1 (en)	2003-10-15	2005-04-28	Cerus Corporation	Listeria-based EphA2 vaccines
DE10354115A1 (en) *	2003-11-19	2005-07-21	Beiersdorf Ag	New use of surfactant systems to reduce damage to the skin's own enzymes
EP1689346A4 (en) *	2003-11-20	2007-11-21	Medimmune Inc	EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USING SAME
WO2005056766A2 (en)	2003-12-04	2005-06-23	Medimmune, Inc.	TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
WO2005067460A2 (en)	2003-12-24	2005-07-28	Medimmune, Inc.	Epha2 vaccines
AU2005245896A1 (en)	2004-05-14	2005-12-01	Receptor Biologix, Inc.	Cell surface receptor isoforms and methods of identifying and using the same
JP2008510007A (en)	2004-08-16	2008-04-03	メディミューン，インコーポレーテッド	Eph receptor Fc variants with enhanced antibody-dependent cellular cytotoxic activity
WO2006052409A2 (en)	2004-10-23	2006-05-18	Case Western Reserve University	Peptide and small molecule agonists of epha and their uses
JP2008518021A (en)	2004-10-27	2008-05-29	メディミューン，インコーポレーテッド	Use of EPHA2 and EPHRINA1 modulators for the treatment and prevention of infections
AU2005299355A1 (en)	2004-10-27	2006-05-04	Medimmune, Llc	Modulation of antibody specificity by tailoring the affinity to cognate antigens
JP2008518022A (en)	2004-10-27	2008-05-29	メディミューン，インコーポレーテッド	EphA2 and ephrinA1 modulators for treating fibrosis related diseases
US7569672B2 (en) *	2005-02-04	2009-08-04	Raven Biotechnologies, Inc.	Antibodies that bind to EphA2 and methods of use thereof
JP2008536815A (en)	2005-03-14	2008-09-11	メディミューン，エルエルシー	Macromolecules containing thioether bridges
EP1888106A4 (en)	2005-05-20	2009-01-14	Univ Illinois	COMPOSITIONS AND METHODS FOR TREATING EPHRIN SIGNALING WITH CUPREDOXINES
KR20080080482A (en) *	2005-09-07	2008-09-04	메디뮨 엘엘씨	EPH receptor receptor conjugated with toxin
WO2007035451A2 (en)	2005-09-16	2007-03-29	The Board Of Trustees Of The Leland Stanford Junior University	Methods of modulating angiogenesis and screening compounds for activity in modulating angiogenesis
EP1968998A4 (en) *	2005-12-21	2010-01-27	Medimmune Llc	Affinity optimized epha2 agonistic antibodies and methods of use thereof
EP1981532A4 (en)	2005-12-21	2010-06-30	Medimmune Llc	Epha2 bite molecules and uses thereof
CA2641026A1 (en)	2006-02-01	2007-08-09	The Johns Hopkins University	Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US20080003210A1 (en) *	2006-03-13	2008-01-03	Medimmune, Inc.	Non-human primate receptor tyrosine kinases
WO2007146968A2 (en)	2006-06-12	2007-12-21	Trubion Pharmaceuticals, Inc.	Single-chain multivalent binding proteins with effector function
CN101622276B (en)	2006-07-18	2015-04-22	赛诺菲-安万特	Antagonistic antibodies against EPHA2 for the treatment of cancer
WO2008066498A1 (en)	2006-12-01	2008-06-05	Agency For Science, Technology And Research	Cancer-related protein kinases
WO2008070042A2 (en)	2006-12-04	2008-06-12	Medimmune, Inc.	High potency recombinant antibodies, methods for producing them and use in cancer therapy
US20100093626A1 (en)	2006-12-15	2010-04-15	Bingcheng Wang	Peptide and small molecule agonists of epha and their uses in disease
US20080199426A1 (en) *	2007-01-11	2008-08-21	Sukhatme Vikas P	Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
JP2010523139A (en)	2007-04-13	2010-07-15	株式会社サイトパスファインダー	Compound profiling method
AU2008265928A1 (en)	2007-06-18	2008-12-24	Medimmune, Llc	Synergistic treatment of cells that express EphA2 and ErbB2
US20120039870A9 (en)	2007-09-07	2012-02-16	Ablynx N.V.	Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
WO2009052830A1 (en)	2007-10-22	2009-04-30	Genmab A/S	Novel antibody therapies

2008
- 2008-08-29 PL PL08828482T patent/PL2199390T3/en unknown
- 2008-08-29 LT LTEP08828482.3T patent/LT2199390T/en unknown
- 2008-08-29 WO PCT/JP2008/065486 patent/WO2009028639A1/en not_active Ceased
- 2008-08-29 HR HRP20170407TT patent/HRP20170407T1/en unknown
- 2008-08-29 ES ES08828482.3T patent/ES2618316T3/en active Active
- 2008-08-29 KR KR1020147036821A patent/KR101561403B1/en not_active Expired - Fee Related
- 2008-08-29 BR BRPI0816094 patent/BRPI0816094A2/en not_active Application Discontinuation
- 2008-08-29 NZ NZ583966A patent/NZ583966A/en not_active IP Right Cessation
- 2008-08-29 RU RU2010111896/10A patent/RU2525133C2/en not_active IP Right Cessation
- 2008-08-29 EP EP08828482.3A patent/EP2199390B1/en not_active Not-in-force
- 2008-08-29 CN CN200880114621.5A patent/CN101848998B/en not_active Expired - Fee Related
- 2008-08-29 KR KR1020157008278A patent/KR101561417B1/en not_active Expired - Fee Related
- 2008-08-29 KR KR1020157008277A patent/KR101561416B1/en not_active Expired - Fee Related
- 2008-08-29 CA CA2698146A patent/CA2698146C/en not_active Expired - Fee Related
- 2008-08-29 MY MYPI20100815 patent/MY150621A/en unknown
- 2008-08-29 MX MX2010002248A patent/MX2010002248A/en active IP Right Grant
- 2008-08-29 PT PT88284823T patent/PT2199390T/en unknown
- 2008-08-29 KR KR1020107004260A patent/KR101521668B1/en not_active Expired - Fee Related
- 2008-08-29 HU HUE08828482A patent/HUE032301T2/en unknown
- 2008-08-29 DK DK08828482.3T patent/DK2199390T3/en active
- 2008-08-29 JP JP2009530190A patent/JP5312333B2/en not_active Expired - Fee Related
- 2008-08-29 AU AU2008292352A patent/AU2008292352B2/en not_active Ceased
- 2008-08-29 SI SI200831748A patent/SI2199390T1/en unknown
- 2008-08-29 TW TW97133095A patent/TWI443109B/en not_active IP Right Cessation
2010
- 2010-02-24 ZA ZA2010/01340A patent/ZA201001340B/en unknown
- 2010-02-25 US US12/713,041 patent/US8449882B2/en not_active Expired - Fee Related
- 2010-02-28 IL IL204211A patent/IL204211A/en not_active IP Right Cessation
- 2010-03-11 CO CO10028981A patent/CO6180469A2/en active IP Right Grant
2013
- 2013-05-22 US US13/899,996 patent/US9150657B2/en not_active Expired - Fee Related
- 2013-06-05 JP JP2013118547A patent/JP5688433B2/en not_active Expired - Fee Related
2015
- 2015-10-05 US US14/875,360 patent/US20160031987A1/en not_active Abandoned
2017
- 2017-03-16 CY CY20171100336T patent/CY1118763T1/en unknown

Also Published As

Publication number	Publication date
BRPI0816094A2 (en)	2015-03-03
US8449882B2 (en)	2013-05-28
CA2698146C (en)	2016-12-20
TW200916480A (en)	2009-04-16
IL204211A (en)	2016-04-21
EP2199390B1 (en)	2016-12-21
HUE032301T2 (en)	2017-09-28
KR20100057018A (en)	2010-05-28
KR20150008931A (en)	2015-01-23
SI2199390T1 (en)	2017-02-28
KR101561416B1 (en)	2015-10-16
JP2013198492A (en)	2013-10-03
PT2199390T (en)	2017-03-15
KR101561403B1 (en)	2015-10-16
NZ583966A (en)	2012-04-27
ES2618316T3 (en)	2017-06-21
CY1118763T1 (en)	2017-07-12
CN101848998B (en)	2016-08-03
JPWO2009028639A1 (en)	2010-12-02
US20140212439A1 (en)	2014-07-31
CN101848998A (en)	2010-09-29
KR20150041811A (en)	2015-04-17
AU2008292352B2 (en)	2012-03-08
AU2008292352A1 (en)	2009-03-05
RU2010111896A (en)	2011-10-10
CO6180469A2 (en)	2010-07-19
MY150621A (en)	2014-02-14
EP2199390A1 (en)	2010-06-23
LT2199390T (en)	2017-03-10
US20100183618A1 (en)	2010-07-22
RU2525133C2 (en)	2014-08-10
KR101561417B1 (en)	2015-10-16
ZA201001340B (en)	2010-11-24
MX2010002248A (en)	2010-03-25
US9150657B2 (en)	2015-10-06
KR101521668B1 (en)	2015-05-28
TWI443109B (en)	2014-07-01
JP5312333B2 (en)	2013-10-09
EP2199390A4 (en)	2012-12-12
DK2199390T3 (en)	2017-04-03
WO2009028639A1 (en)	2009-03-05
HRP20170407T1 (en)	2017-05-05
CA2698146A1 (en)	2009-03-05
US20160031987A1 (en)	2016-02-04
JP5688433B2 (en)	2015-03-25
KR20150041186A (en)	2015-04-15

Publication	Publication Date	Title
ZA201001340B (en)	2010-11-24	Anti-epha2 antibody
EP2138576A4 (en)	2011-02-23	Anti-claudin-4 antibody
PL2146745T3 (en)	2015-11-30	penta-specific antibody
GB0708002D0 (en)	2007-06-06	Antibodies
EP2241578A4 (en)	2012-09-12	Anti-cldn6 antibody
ZA201102119B (en)	2011-12-28	Improved antibody libraies
IL229512A0 (en)	2013-12-31	Anti-vegf antibodies
IL234081B (en)	2019-02-28	Cross - species - specific cd3 - epsilon binding antibody
SG10201605394SA (en)	2016-08-30	Modified Antibody Constant Region
IL201340A (en)	2015-11-30	Cross-species-specific cd3- epsilon binding antibody
EP2077859A4 (en)	2010-11-24	Antibody formulation
IL206103A (en)	2016-07-31	Antibody formulation
SI2200700T1 (en)	2016-04-29	Novel antibodies
IL204835A0 (en)	2010-11-30	Humanized antibody
GB0821100D0 (en)	2008-12-24	Antibodies
IL205073A0 (en)	2010-11-30	Anti-bst2 antibody
GB0718737D0 (en)	2007-11-07	Antibodies
IL207581A0 (en)	2010-12-30	Anti-tyrp1 antibodies
GB0702888D0 (en)	2007-03-28	Novel Antibodies
GB0615662D0 (en)	2006-09-13	Antibody
GB0711635D0 (en)	2007-07-25	Hydrocarbons
ZA201007976B (en)	2012-02-29	Anti-pirb antibodies
GB0818356D0 (en)	2008-11-12	Antibodies
GB0911770D0 (en)	2009-08-19	Antibody
KG1098C1 (en)	2008-11-29	Towel-drying construction